Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

437 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Infliximab salvage therapy after failure of ciclosporin in corticosteroid-refractory ulcerative colitis: a multicentre study.
Chaparro M, Burgueño P, Iglesias E, Panés J, Muñoz F, Bastida G, Castro L, Jiménez C, Mendoza JL, Barreiro-de Acosta M, Senent SG, Gomollón F, Calvet X, García-Planella E, Gómez M, Hernández V, Hinojosa J, Mañosa M, Nyssen OP, Gisbert JP. Chaparro M, et al. Among authors: hinojosa j. Aliment Pharmacol Ther. 2012 Jan;35(2):275-83. doi: 10.1111/j.1365-2036.2011.04934.x. Epub 2011 Dec 5. Aliment Pharmacol Ther. 2012. PMID: 22142227 Free article.
Efficacy and safety of short-term adalimumab treatment in patients with active Crohn's disease who lost response or showed intolerance to infliximab: a prospective, open-label, multicentre trial.
Hinojosa J, Gomollón F, García S, Bastida G, Cabriada JL, Saro C, Ceballos D, Peñate M, Gassull MA; Spanish Scientific Group on Crohn's Disease and Ulcerative Colitis. Hinojosa J, et al. Aliment Pharmacol Ther. 2007 Feb 15;25(4):409-18. doi: 10.1111/j.1365-2036.2006.03232.x. Aliment Pharmacol Ther. 2007. PMID: 17269996 Free article. Clinical Trial.
Phenotype and natural history of elderly onset inflammatory bowel disease: a multicentre, case-control study.
Mañosa M, Calafat M, de Francisco R, García C, Casanova MJ, Huelín P, Calvo M, Tosca J, Fernández-Salazar L, Arajol C, Zabana Y, Bastida G, Hinojosa J, Márquez L, Barreiro-de-Acosta M, Calvet X, Monfort D, Gómez-Garcia MR, Rodríguez E, Huguet JM, Rojas-Feria M, Hervias D, Atienza R, Busquets D, Zapata E, Dueñas C, Charro M, Martínez-Cerezo FJ, Plaza R, Vázquez JM, Gisbert JP, Cañete F, Cabré E, Domènech E; GETECCU. Mañosa M, et al. Among authors: hinojosa j. Aliment Pharmacol Ther. 2018 Mar;47(5):605-614. doi: 10.1111/apt.14494. Epub 2018 Jan 25. Aliment Pharmacol Ther. 2018. PMID: 29369387
Risk of Immunomediated Adverse Events and Loss of Response to Infliximab in Elderly Patients with Inflammatory Bowel Disease: A Cohort Study of the ENEIDA Registry.
Calafat M, Mañosa M, Ricart E, Nos P, Iglesias-Flores E, Vera I, López-Sanromán A, Guardiola J, Taxonera C, Mínguez M, Martín-Arranz MD, de Castro L, de Francisco R, Rivero M, Garcia-Planella E, Calvet X, García-López S, Márquez L, Gomollón F, Barrio J, Esteve M, Muñoz F, Gisbert JP, Gutiérrez A, Hinojosa J, Argüelles-Arias F, Busquets D, Bujanda L, Pérez-Calle JL, Sicilia B, Merino O, Martínez P, Bermejo F, Lorente R, Barreiro-de Acosta M, Rodríguez C, Fe García-Sepulcre M, Monfort D, Cañete F, Domènech E; ENEIDA Study Group of GETECCU. Calafat M, et al. Among authors: hinojosa j. J Crohns Colitis. 2022 Jul 14;16(6):946-953. doi: 10.1093/ecco-jcc/jjab213. J Crohns Colitis. 2022. PMID: 34864947
Observational study on the efficacy of adalimumab for the treatment of ulcerative colitis and predictors of outcome.
García-Bosch O, Gisbert JP, Cañas-Ventura A, Merino O, Cabriada JL, García-Sánchez V, Gutiérrez A, Nos P, Peñalva M, Hinojosa J, García-Planella E, Muñoz F, Calvet X, Panés J. García-Bosch O, et al. Among authors: hinojosa j. J Crohns Colitis. 2013 Oct;7(9):717-22. doi: 10.1016/j.crohns.2012.10.004. Epub 2012 Nov 8. J Crohns Colitis. 2013. PMID: 23142005
Therapeutic guidelines on ulcerative colitis: a GRADE methodology based effort of GETECCU.
Gomollón F, García-López S, Sicilia B, Gisbert JP, Hinojosa J; Grupo Espa˜nol de Trabajo en Enfermedad de Crohn y Colitis Ulcerosa. Gomollón F, et al. Among authors: hinojosa j. Gastroenterol Hepatol. 2013 Feb;36(2):104-14. doi: 10.1016/j.gastrohep.2012.09.006. Epub 2013 Jan 14. Gastroenterol Hepatol. 2013. PMID: 23332546
Safety of thiopurine therapy in inflammatory bowel disease: long-term follow-up study of 3931 patients.
Chaparro M, Ordás I, Cabré E, Garcia-Sanchez V, Bastida G, Peñalva M, Gomollón F, García-Planella E, Merino O, Gutiérrez A, Esteve M, Márquez L, Garcia-Sepulcre M, Hinojosa J, Vera I, Muñoz F, Mendoza JL, Cabriada JL, Montoro MA, Barreiro-de Acosta M, Ceña G, Saro C, Aldeguer X, Barrio J, Maté J, Gisbert JP. Chaparro M, et al. Among authors: hinojosa j. Inflamm Bowel Dis. 2013 Jun;19(7):1404-10. doi: 10.1097/MIB.0b013e318281f28f. Inflamm Bowel Dis. 2013. PMID: 23665964
Clinical outcome after anti-tumour necrosis factor therapy discontinuation in 1000 patients with inflammatory bowel disease: the EVODIS long-term study.
Casanova MJ, Chaparro M, Nantes Ó, Benítez JM, Rojas-Feria M, Castro-Poceiro J, Huguet JM, Martín-Cardona A, Aicart-Ramos M, Tosca J, Martín-Rodríguez MDM, González-Muñoza C, Mañosa M, Leo-Carnerero E, Lamuela-Calvo LJ, Pérez-Martínez I, Bujanda L, Hinojosa J, Pajares R, Argüelles-Arias F, Pérez-Calle JL, Rodríguez-González GE, Guardiola J, Barreiro-de Acosta M, Gisbert JP; EVODIS Study Group*. Casanova MJ, et al. Among authors: hinojosa j. Aliment Pharmacol Ther. 2021 Jun;53(12):1277-1288. doi: 10.1111/apt.16361. Epub 2021 May 7. Aliment Pharmacol Ther. 2021. PMID: 33962482
437 results